Eltrombopag/eltrombopag potential side effects and risks

Eltrombopag/ Eltrombopag is a drug for the treatment of specific thrombocytopenia (ITP), which can effectively deal with idiopathic thrombocytopenia caused by an overactive immune system and the thrombocytopenia related to chronic liver disease. It stimulates the bone marrow and prompts the body to produce more platelets, thereby increasing the platelet count and preventing bleeding.

The use of any medication may be associated with certain risks. In clinical studies of eltrombopag, the most commonly reported side effects in adult patients included nausea, diarrhea, and abnormally elevated blood levels of certain liver enzymes. More serious potential risks include bleeding, liver damage, and thromboembolic complications. For children, the most common side effects include nose and throat infections, cough, fever, abdominal or mouth and throat pain, toothache, and runny nose.

In patients with severe aplastic anemia, the use of eltrombopag may also cause a series of side effects. The most commonly reported side effects by these patients include headache, dizziness, cough, pain in the abdomen or mouth and throat, nausea, diarrhea, joint pain, pain in the extremities, fatigue, fever, and abnormalities in the blood levels of certain liver enzymes.

The side effects faced by patients with chronic hepatitis C-related thrombocytopenia who receive interferon and eltrombopag concomitantly may be more complex. The most commonly reported side effects by these patients range from headache, anemia, decreased appetite, cough, nausea, diarrhea, increased bilirubin levels in the blood, hair loss, itching, muscle pain, fever, fatigue, flu-like symptoms, weakness, chills, and swelling of body parts. More serious risks also involve liver problems and thromboembolic complications.